


# CLINICAL TRIAL

RAAV2/2-ND4



Low vision

**An open label dose escalation clinical trial to evaluate the safety and the tolerability of gs010 (rAAV2/2-ND4) in patients with leber hereditary optic neuropathy due to mutations in the mitochondrial nadh dehydrogenase 4 gene**

Rare Eye Disease concerned by the trial :  
Leber hereditary optic neuropathy

Status of the trial : completed  
Orphan drug recognition : N/A

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date : 13/10/2016



Inclusion closing date (previsional) : 12/12/2021

Children



Adults



## Within ERN-EYE members



Principal location of the trial :

**CHNO des XV XX**  
28 rue de charenton  
75012 Paris  
France

[Contact details](#)




Principal investigator name :

Dr Catherine VIGNAL



Other investigators :

None



Funder type : Gene therapy company

[More informations](#)